Pilot Study of Hemoglobin Based Oxygen Therapeutics in Elective Coronary Revascularization

Inclusion Criteria: * Written informed consent provided before initiation of any study-related procedure, and before any pre-procedural sedation, and agreement to comply with all protocol-specified procedures * Acute Coronary Syndrome (Stable and unstable angina or non ST segment Elevation Myocardial Infarction (UA/non-STEMI) \[Braunwald class I-III Class B\], Appendix 1). * Single vessel disease of the Left Coronary Artery (LCA) * One vessel disease of the Right Coronary Artery (RCA) * Have a single de novo lesion * Older than 18 years and younger than 75 years of age * Eligible to undergo PCI on the target vessel Exclusion Criteria: * Previous Q-wave myocardial infarction * Congestive heart failure with Left ventricular Ejection Fraction \<35% * Confirmed pregnancy * Anemia to a hemoglobin level \<8.5g/dl * Systemic mastocytosis * History of known haemorrhagic stroke at any time or any stroke less than or equal to 30 days prior to randomization * Severe hypertension (\>180/110mmHG) not adequately controlled by antihypertensive therapy at time of study entry * Need for mechanical ventilation * Renal impairment: Creatinine \> 1.6mg/dl * Known history of COPD with FEV 1s \< 1.0 liter * Contra-indications to the use of adenosine, i.e.History of bronchospasm and/or ongoing therapy with theophylline derivatives, \>1 degree atrioventricular block in the absence of a functioning electronic pacemaker and treatment with dipyridamole within the prior 24 hours * Patients with significant hemodynamic compromise and/or cardiogenic shock requiring inotropic or pressor support or pulmonary edema * History of or clinical documentation of severe aortic/mitral valve stenosis, significant aortic valve insufficiency * Participation in another trial with an investigational drug or device (of other investigations) including the follow-up period, within the last 30 days before enrollment * Inability or unwillingness to perform 30 day follow up * Concomitant disease that interferes with prognosis (life expectancy of less than or equal to 6 months * Contra-indications to standard drugs for coronary intervention and coronary heart disease: aspirin, heparin, low molecular weight heparin, clopidogrel, contrast dye * Patient weight \> 110kg